{"disease":{"id":"conditions","name":"conditions"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"omeprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prilosec","generic_name":"omeprazole","company_name":"AstraZeneca (originally Astra AB)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"Proton pump inhibitor (PPI)","quality_score":50,"revenue":"1041.0","mechanism":"Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"algeldrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"ALGELDRATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"algeldrate","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"prevacid","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prevacid","company_name":"Vanderbilt University Medical Center","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pantoprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protonix","generic_name":"pantoprazole","company_name":"Generic (originally Byk Gulden/Altana/Nycomed)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"Proton pump inhibitor (PPI)","quality_score":58,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump (H+/K+ ATPase), suppressing stomach acid secretion."},{"drug_id":"carbaldrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"carbaldrate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"carbaldrate","quality_score":null,"revenue":null,"mechanism":"Carbaldrate works by reducing stomach acid production."},{"drug_id":"almasilate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gelusil","generic_name":"ALMASILATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"almasilate","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"alum","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Alum","generic_name":"Alum","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"protonix-iv","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pantoprazole Sodium","generic_name":"Pantoprazole Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"(H+, K+)-ATPase enzyme","drug_class":"Proton pump inhibitor (PPI)","quality_score":69,"revenue":null,"mechanism":"Pantoprazole suppresses gastric acid by covalently binding the (H+, K+)-ATPase enzyme at parietal cells."},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of eye conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of psychiatric conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of cardiovascular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of respiratory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of gastrointestinal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of genitourinary conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of musculoskeletal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of dermatological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of allergic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of immunological conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of infectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of parasitic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of fungal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of viral conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of bacterial conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of prion conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of amyloid conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodevelopmental conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuromuscular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinfectious conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neuroinflammatory conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of neurodegenerative conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rabeprazole-40-mg","indication_name":"Pathological Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rabeprazole 40 mg","generic_name":"rabeprazole-40-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"H+/K+ ATPase","drug_class":"Proton Pump Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with heart conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pfizer-biontech-covid-19-mrna-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pfizer-BioNTech COVID-19 mRNA vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":38,"revenue":null,"mechanism":"mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response"},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain underlying medical conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)","generic_name":"bnt162b2-omi-xbb-1-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"omeprazol","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omeprazol","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pantoprazol","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pantoprazol","company_name":"Northern Orthopaedic Division, Denmark","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"loteprednol-etabonate","indication_name":"Steroid-responsive inflammatory conditions of the eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lansoprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevacid","generic_name":"lansoprazole","company_name":"Generic (originally Takeda)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase","drug_class":"Proton pump inhibitor (PPI)","quality_score":null,"revenue":null,"mechanism":"Irreversibly inhibits the gastric proton pump to suppress acid secretion."},{"drug_id":"n-acetyltyrosine","indication_name":"Nutritional support in stress conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"N-Acetyl-Tyrosine","generic_name":"N-Acetyltyrosine","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Amino Acid [EPC]","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"orphenadrine","indication_name":"Acute painful musculoskeletal conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1219","indication_name":"Treatment of Pathological Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RABEPRAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"fluorometholone-acetate","indication_name":"Steroid-responsive inflammatory conditions of the eye","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flarex","generic_name":"FLUOROMETHOLONE ACETATE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Steroid-responsive inflammatory ocular conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Inflammatory conditions of the palpebral and bulbar conjunctiva","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"hydroxyzine-pamoate","indication_name":"Management of pruritus due to allergic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYZINE PAMOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"bacillus-subtilis","indication_name":"Skin and Lung Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bacillus subtilis","company_name":"DreamTec Research Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"bacillus-subtilis","indication_name":"Other Internal Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bacillus subtilis","company_name":"DreamTec Research Limited","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"dexrabeprazole","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexpure","generic_name":"dexrabeprazole","company_name":"","drug_phase":"unknown","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Proton Pump Inhibitors","quality_score":null,"revenue":null,"mechanism":"Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"sodium-citrate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bss","generic_name":"SODIUM CITRATE","company_name":"B Braun","drug_phase":"marketed","molecular_target":"Calcium","drug_class":"sodium citrate","quality_score":51,"revenue":null,"mechanism":"ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade."},{"drug_id":"magnesium-silicate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gaviscon","generic_name":"MAGNESIUM SILICATE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"magnesium silicate","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"magnesium-carbonate","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"MAGNESIUM CARBONATE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"magnesium-hydroxide","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Milk of Magnesia","generic_name":"magnesium hydroxide","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Gastric acid (direct neutralization) + osmotic effect in intestine","drug_class":"Osmotic laxative, Antacid","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ranitidine","indication_name":"Gastric Hypersecretory Conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zantac","generic_name":"ranitidine","company_name":"GSK (originally Glaxo)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor","drug_class":"H2 receptor antagonist","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to other conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."}],"pipeline":[],"offLabel":[],"totalMarketed":267,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06617533","title":"Evaluation of the Primary Care First Model","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25000000,"lead_sponsor_name":"Mathematica Policy Research, Inc.","has_results":false},{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT05097066","title":"Patterns and Outcomes of Neurosurgery in England Over a Five-year Period","phase":"","overall_status":"COMPLETED","enrollment_count":371418,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT06420453","title":"How Long Can Labor Last? Person Centred Care During Labor to Increase Safety for Women and Newborn","phase":"","overall_status":"COMPLETED","enrollment_count":300000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06623799","title":"Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"QHSLab, Inc.","has_results":false},{"nct_id":"NCT06784713","title":"DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN","phase":"","overall_status":"COMPLETED","enrollment_count":127277,"lead_sponsor_name":"University of Tartu","has_results":false},{"nct_id":"NCT05013944","title":"AnovaOS Network Powered Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Anova Enterprises, Inc","has_results":false},{"nct_id":"NCT05952271","title":"Herpes Zoster Hospitalizations in Italy","phase":"","overall_status":"UNKNOWN","enrollment_count":72000,"lead_sponsor_name":"University of L'Aquila","has_results":false},{"nct_id":"NCT01837693","title":"Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2","phase":"NA","overall_status":"COMPLETED","enrollment_count":41127,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT06583694","title":"Bangkok Noi District Electronic Health Database With Socioeconomic Factors From Bangkok Noi Model Project (BANMOP)","phase":"","overall_status":"COMPLETED","enrollment_count":21286,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT04717349","title":"Data Collection Study of Pediatric and Adolescent Gynecology Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04017273","title":"Older Emergency Department Users and Hospitalization After an Index Visit: Results of ER2 Database","phase":"","overall_status":"UNKNOWN","enrollment_count":10971,"lead_sponsor_name":"Jewish General Hospital","has_results":false},{"nct_id":"NCT06476470","title":"Taiwan Interstitial Lung Disease Multi-center Investigation and Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT04706481","title":"Archival of Human Biological Samples in CU-Med Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT05952999","title":"Analysis of the Virtual Acute Care at Home Experience","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9654,"lead_sponsor_name":"OSF Healthcare System","has_results":false},{"nct_id":"NCT01568658","title":"Genetic and Physical Study of Childhood Nerve and Muscle Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":9300,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07215897","title":"Evaluating Covered California's Grocery Support Program","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6975,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07049861","title":"Advancing Biopsychosocial Care Training Initiative","phase":"NA","overall_status":"RECRUITING","enrollment_count":6200,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06527703","title":"An International Prospective, Observational, Multi-centre Study on the Duration of Pre-operative Liquid Fasting","phase":"","overall_status":"COMPLETED","enrollment_count":5100,"lead_sponsor_name":"Mater Dei Hospital, Malta","has_results":false},{"nct_id":"NCT02993120","title":"Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":5006,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04065620","title":"Ambulatory Blood Pressure in HFPEF Outcomes Global Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT05367115","title":"Verification of the Epidemiology and Mortality of Rare Diseases in Taiwan With Real-world Evidence","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT07477197","title":"Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT03626389","title":"Clinical Course of Patients Receiving Physiotherapy Services in Primary Health Care","phase":"","overall_status":"COMPLETED","enrollment_count":4985,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT03313583","title":"French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":4720,"lead_sponsor_name":"Etablissement Français du Sang","has_results":false},{"nct_id":"NCT05289206","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4446,"lead_sponsor_name":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","has_results":false},{"nct_id":"NCT06456749","title":"Xishui Project for IDM of COPD and Comorbidities","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT03072472","title":"BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities","phase":"NA","overall_status":"COMPLETED","enrollment_count":3221,"lead_sponsor_name":"South Tyneside and Sunderland NHS Foundation Trust","has_results":false},{"nct_id":"NCT05185232","title":"Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult Centered Care","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT04709120","title":"Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":2968,"lead_sponsor_name":"Eurasian Association of Therapists","has_results":false},{"nct_id":"NCT07011368","title":"Empowering Healthy Lifestyle Personalised Intervention to Prevent and Control Obesity: The HealthyW8 Project","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2720,"lead_sponsor_name":"Fundació d'investigació Sanitària de les Illes Balears","has_results":false},{"nct_id":"NCT06323187","title":"Optimization of Cervical Collections in Pregnancy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Dr. Sascha Drewlo","has_results":false},{"nct_id":"NCT05534178","title":"Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Vall d'Hebron Institute of Oncology","has_results":false},{"nct_id":"NCT05094180","title":"Open Label Randomized Clinical Trial to Assess the Safety of Teleconsultation","phase":"NA","overall_status":"RECRUITING","enrollment_count":2136,"lead_sponsor_name":"Consorci Sanitari de l'Alt Penedès i Garraf","has_results":false},{"nct_id":"NCT06402409","title":"Exploring Multimorbidity in Patients With Spinal Pain","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Jacob Christiansen Gandløse","has_results":false},{"nct_id":"NCT05295862","title":"Giessen Stroke Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT04873258","title":"Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Richmond Research Institute","has_results":false},{"nct_id":"NCT03160274","title":"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":false},{"nct_id":"NCT07007299","title":"Safety and Efficacy of Integrative Korean Medicine Treatment for Elderly After Traffic Accident","phase":"","overall_status":"COMPLETED","enrollment_count":1788,"lead_sponsor_name":"Jaseng Medical Foundation","has_results":false},{"nct_id":"NCT04564274","title":"COV2Base-A Rare Disease by COVID Study","phase":"","overall_status":"COMPLETED","enrollment_count":1748,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03544866","title":"The Impact of Pediatric Skin Disorders: The \"Big\" Study","phase":"","overall_status":"COMPLETED","enrollment_count":1666,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06806371","title":"PREDICTORS of CARDIOVASCULAR OUTCOMES in INDIVIDUALS with DIFFERENT OBESITY PHENOTYPES","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Ryazan State Medical University","has_results":false},{"nct_id":"NCT07094737","title":"The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P) Registry: An Observational Study on Cardiac Rehabilitation in Patients With Coronary Disease or Heart Failure","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT06968403","title":"Community Emotional Intelligence Network to Address Mental Health Among Coastal Bangladeshis","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","has_results":false},{"nct_id":"NCT06507527","title":"Frailty in Outpatient Digestive Endoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":1474,"lead_sponsor_name":"Parc de Salut Mar","has_results":false},{"nct_id":"NCT05282654","title":"Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06696209","title":"To Evaluate the Best Metric for Inspection Time During a Diagnostic and/or Surveillance Upper Gastrointestinal Endoscopy (Age ≥ 18 Years, Informed Consent), Between Total Inspection Time Versus Withdrawal Time, for the Identification of Malignant Lesions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1290,"lead_sponsor_name":"Portuguese Oncology Institute, Coimbra","has_results":false},{"nct_id":"NCT02227004","title":"Safety of Magnetic Resonance Imaging in Patients With Pacemakers and Defibrillators","phase":"","overall_status":"COMPLETED","enrollment_count":1275,"lead_sponsor_name":"Johns Hopkins University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}